For many years, genetically obese mouse strains have provided models for human obesity. The A vy a-agouti mouse, one of the oldest obese mouse models, is characterized by maturity-onset obesity and diabetes as a result of ectopic expression of the secreted protein hormone, agouti protein. Agouti protein is normally expressed in hair follicles to regulate pigmentation through antagonism of the melanocortin-1 receptor, but in-vitro studies have demonstrated that the hormone also has potent antagonist activity for the melanocortin-4 receptor (MC4-R). Subsequent development of the MC4-R knockout mouse model demonstrated that MC4-R plays a role in weight homeostasis as these mice recapitulated the metabolic defects of the agouti mouse. Further evidence for this hypothesis was obtained from pharmacological studies utilizing peptides with MC4-R agonist activity, that inhibitied food intake (when administered intracerebrally). Additional studies with peptide antagonists have now implicated the MC4-R in the leptin signalling pathway. Finally, evidence that the MC4-R may play a role in human obesity has been obtained from the identi®cation of a dis-functional variant of the receptor in genetically obese subjects.
Introduction
Obesity is reaching epidemic status in the developed world and is rapidly threatening the near-developed regions of the globe. The clinically obese comprise nearly 30% of the total population in the US alone 1 and it is estimated over $60 billion are spent annually in treatments for this disease, 2 which is characterized by increased storage of energy input as adipose tissue as a consequence of unbalanced energy intake and energy expenditure. Obese patients suffer from an increased risk of a number of severe and debilitating diseases including non-insulin dependent diabetes mellitus (NIDDM), hypertension, hyperlipidemia, sleep apnea, and certain cancers. 3 While previous generations regarded obesity as a social disease that could be remedied with appropriate diet and exercise regimens, it is now clear that human obesity is a multifactorial disease with both environmental and genetic components. Studies in human populations 4 suggest that at least 35% (and potentially as high as 50%) of the obese population is genetically predisposed to become overweight. This segment of the population is most likely to bene®t from therapeutic intervention and it is hoped that with proper diet and exercise, therapeutic treatment will allow for longterm weight reduction and weight maintenance.
There has been an explosion in obesity research and with this has come an understanding of the molecular mechanisms that underly the disease. This explosion was sparked by the cloning of the ob gene from the obese mouse model obaob 5 and the subsequent demonstration that the protein product is a centrally active hormone. 6 These initial observations have led to an increasingly complex view of the factors and regulatory processes that govern weight homeostasis in which the OB protein (or leptin) plays a central role coordinating a number of metabolic and reproductive functions.
7 ± 10 Use of mouse genetics as a predictor and model of human disease has provided the framework for the identi®cation of novel drug discovery targets. Our goal in this report is to describe the current understanding of the weight regulation processes underlying another genetically obese mouse model, the agouti viable yellow A vy a-mouse.
Agouti mouse model
The A vy a-mouse is the oldest known mouse model of obesity and was initially prized by mouse fanciers for its golden yellow coat color (Figure 1) . 11 In addition to the change in coat color, these mice display an ageonset (10 ± 20 weeks) metabolic defect characterized by hyperphagia, increased adiposity, hyperglycemia, hyperinsulinemia and increased somatic growth. Unlike other mouse models, the increased adipocyte mass results from adipocyte hypertropy 12 Ðan attribute that, along with the age-onset of development, closely resembles the characteristics most commonly observed in human obesity.
The underlying cause of the A vy a-mouse metabolic defect remained an enigma until the early 1990s. The yellow coat color strongly suggested that the pigmentation regulatory pathways governed by the melanocortin-1 receptor (MC1-R) were affected. Primarily expressed in the skin, the MC1-R is a G-protein coupled receptor which regulates pigmentation in response to the melanocyte stimulating hormone (a-MSH), a potent agonist of MC1-R. 13 Agonism of the MC1-R results in eumelanin production (and therefore black pigmentation) whereas antagonism produces phaeomelanin (resulting in bleaching of the skin color). There are ®ve known melanocortin receptors based on sequence homology that ranges from 35 ± 60% homology between family members. 13 The MC2-R, also known as the adrenocorticotropin hormone (ACTH) receptor, is expressed in the adrenal cortex and regulates corticosteroid synthesis in response to ACTH levels. The MC3-R and MC4-R are both expressed in the central nervous system (CNS), and little was known about the function of these receptors when the agouti gene was cloned. The MC5-R is expressed in speci®c exocrine glands throughout the body (for example, Harderian and perputial glands) and has been implicated in the control of lipid and pheromone production in these sites.
14 Melanocyte stimulating hormones are produced from pro-opiomelanocortin (POMC), a prohormone of 131 amino acids that is processed into three classes of hormones; the melanocortins (a, b, and g), ACTH and various endorphins (for example, lipotropin). 13 POMC is produced primarily in the pituitary, but also in the arcuate nucleus of the hypothalamus.
The cloning of the agouti gene in 1992 represented a breakthrough for understanding the A vy a-mouse.
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The agouti gene codes for small (131 residues), soluble, secreted protein, that is normally expressed only in the skin, consistent with the premise that this gene plays a role in coat color regulation through MC1-R interactions. Pharmacological studies on the puri®ed protein product con®rmed this assumption. The agouti protein was found to be a potent (`2 nM) antagonist for the MC1-R, 16 but interestingly was also found to be a potent anatagonist of the MC4-R. Agouti does not bind to MC2, MC3 or MC 5 receptors. The activity at the MC4-R was puzzling due to the selective tissue expression patterns of agouti and the MC4-R, but careful analysis of the A vy a-mouse identi®ed a mutation in the promoter region of the agouti gene that results in high-level, ectopic expression of the gene. 17 This suggested that the characteristic phenotypes of the A vy a-mouse arise from separable antagonist activities at the MC1-R and MC4-R as shown in Figure 2 ; the yellow coat color from MC1-R antagonism and the observed metabolic defects from MC4-R antagonism. This hypothesis was the foundation for the development of an MC4-R knockout mouse model to directly assess the role of MC4-R in the regulation of weight homeostasis.
Studies of the MC4-R
The phenotype of the MC4-R knockout mouse provided con®rmation of the model depicted in Figure 2 . These mice completely recapitulated the metabolic defect of the A vy a-mice. 18 The MC4-R knockout mice have a normal coat color, but develop age-onset obesity (12 ± 20 weeks) that results from hyperphagia and adipocyte hypertrophy. In addition, the mice become hyperglycemic and hyperinsulinemic in a similar age-dependent manner. Furthermore, these effects are attenuated approx 2-fold in the heterozygote mice ± a ®nding consistent with the expected 2-fold increase in receptor density relative to the knockout mice. The mice have normal corticosteriod concentrations, demonstrating an intact hypothalamic ± pituitary ± adrenal (HPA) axis, but also show an increase in the somatic growth as observed in the agouti mice. The extent of hyperglycemia and hyperinsulinemia observed in the knockout mice is gender dependent, with male offspring exhibiting more severe elevation than females in both cases. The overall phenotype clearly demostrates the separate activities of the agouti protein on the melanocortin (Figure 2 ) and implicates the MC4-R as a regulator of energy balance.
Additional proof of the concept for this model (Figure 2 ) was provided by studies that relied on two cyclic heptapeptide analogs of aMSH, MT-II and SHU-9119, which display potent (`1 nM) MC4-R agonist and antagonist activities, respectively. 19 The authors found that injection of MT-II into the third ventricle of the brain caused a dosedependent inhibition of food intake that was long lasting ( b 8 h) and reversible when co-administered with the antagonist SHU-9119. Intraperitoneal administration of higher doses of MT-II had similar effects on food intake, clearly demonstrating that these molecules, although relatively large (MW b 1300), were capable of crossing the blood ± brain barrier in concentrations high enough to result in ef®cacy. To sum up, these studies provided the ®rst demonstration that MC4-R agonists can inhibit food intake and provide a foundation for the development of small molecule anti-obesity agents.
Evidence for MC4-R involvement in leptin signalling
There were several lines of evidence suggesting the MC4-R played a role in the control of metabolic pathways regulated by leptin. First, agouti mice were highly resistant to leptin effects on food intake inhibition. 20 Second, functional (long-form) ob-R receptors were found in the neurons of the arcuate nucleus that produce POMC, providing a basis for the hypothesis that activation of the leptin signalling pathway in these neurons could result in elevated POMC production and processing to yield MC4-R agonists. 21 In addition, comparative analysis (using cFos immunohistochemistry analysis of brain sections of mice treated with leptin or MC4-R agonist) demonstrated that overlapping activation patterns were observed in a number of sites in the brain, for example, paraventricular nucleus (PVN), dorsomedial hypothalamus (DMH) and the central nucleus of the Amygdala (CeA). 22Y 23 Furthermore, the long duration of action observed in food intake inhibition upon administration of MC4-R agonists, was consistent with similar results observed with leptin dosing ± in both cases, the effects extend well beyond the measured half-life of the administered agent. These observations, while largely circumstantial, led to detailed mechanistic studies of leptin and MC4-R signalling activation.
The ®rst direct evidence that leptin in¯uenced the melanocortin signalling pathway was obtained from in-situ analysis of POMC neurons in the arcuate nucleus of a number of mouse and rat models. 24 ± 26 Expression of POMC was found to be proportional to circulating leptin concentrations in the serum; low concentrations of POMC expression were observed in fasted mice (low leptin concentrations), but POMC expression was elevated in response to rising leptin concentrations after feeding. 24, 26 Acute measurements of POMC levels in Long ± Evans rats were found to be directly in¯uenced by the administration of leptin; after leptin administration, the POMC concentrations rose by nearly 39%. 26 In addition, repeated dosing of ob mice with leptin (single dose 5 d) showed elevated POMC concentrations, when compared to control mice. 25, 26 Similar changes were not observed in the dbadb mouse, demonstrating the requirement for an intact ob-signalling pathway (in this case functional ob-R) for POMC modulation.
Additional evidence for melanocortin effects on leptin signalling was obtained from studies using the antagonist, SHU-9119, in Long-Evans rats. 27 The authors ®rst identi®ed a dose that was suf®cient to interact with the receptor, but below the threshold required for modulation of food intake when administered by intracerebral injection into the thrid ventricle (iv3t, dose 0.5 nmol). Under these conditions, both the control animals and those treated with the antagonist demonstrate normal feeding behavior after injection, while those treated with leptin (3.5 mg) show a signi®cant reduction in food intake after 4 h ( 7 56%). Interestingly, animals subjected to co-administration of the antagonist with leptin exhibit normal feeding behavior, clearly showing a pharmacological blockade of leptin signalling by the antagonist. Similar results were obtained upon assessment of cFos activation in the paraventricular nucleus (PVN) ± a region known to be activated by leptin and the MC4-R receptor. As expected from previous work, 22 animals treated with leptin exhibited a signi®cant activation of cFos nuclei when the mice were pre-treated with vehicle (254% increase), but this effect was completely abolished when the mice were pretreated with SHU-9119. These studies indicate that the MC4-R is downstream of ob-R in the leptin pathway; consistent with the working model shown in Figure 3 . This simple model has support from known mouse models of obesity. At each of the steps in the signalling cascade, there is a Figure 3 Proposed model for MC4-R in the leptin signaling pathway.
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SL Fisher et al known genetic mutation that would inhibit the pathway and result in the expected obesity phenotype. Whilte this model is appealing and correlates well to the data mentioned above, there is a report that challenges its underlying tenets. A genetic cross of the A y aa and the obaob mice was prepared and the phenotype of these mice was examined for leptin sensitivity. 28 Unexpectedly, these mice exhibited a near normal response to leptin administration, when measured as a function of body weight reduction, demonstrating that the leptin signalling pathway remained intact in these animals despite the expected antagonism of the MC4-R by the agouti protein. In addition, deletion of the leptin gene in agouti mice restored the senstivity to leptin administration, suggesting that the development of obesity in the A y aa animals is achieved through a pathway that is independent of leptin signalling. Resolution of the apparent con¯ict between the conclusions of this paper and the data supporting the model in Figure 3 awaits further investigation, but it should be noted that the two studies differ considerably in their design (acute administration vs chronic antagonism by agouti) and in their measurement of leptin ef®cacy (food intake inhibition and cFos activation vs body weight reduction). One possibility is that the amount of endogenous agouti protein present in the hypothalamus is not able to inhibit ob signalling through the MC4-R receptor. In the end, the differing results from the two studies may represent the likely possibility that the MC4-R and the leptin signalling pathways, while clearly connected under some conditions, may not be completely overlapping under all situations.
Other melanocortin effects attributed to MC4-R regulation
Recent studies have suggested that the MC4-R may be involved in the control of additional physiological processes such as grooming behaviour 29, 30 and blood pressure regulation. 31 The conclusions from these studies were bases on selective administration of various MSH analogs (a, b, and g) and the antagonist (SHU-9119) into regions of the brain known to express MC4-R. For example, administration of a-MSH into the dorsal motor nucleus of the vagus nerve (a site where MC4-R is expressed 32 ) results in lower blood pressure and bradycardia. This effect is blocked by administration of SHU-9119. Additional side effects have been noted at high doses of both MT-II and SHU-9119, which includes barrel-rolling in rats and the development of conditioned-taste aversions. 23 These side effects are inconsistent with agonism of the MC4-R. It should be noted that although these compounds were originally reported as speci®c for the MC4-R, 19 subsequent pharmacological studies have shown that both MT-II and SHU-9119 have potent activities at other melanocortin receptors. 33 In addition, there is evidence to suggest that there are additional melanocortin receptors that remain to be identi®ed. 32 As a result, con®rmation of additional MC4-R speci®c regulatory pathways will await the generation of more speci®c compounds and the potential discovery of new melanocortin receptors.
Evidence for melanocortin regulation of human obesity
While the data supporting a role for MC4-R in weight regulation in rodent models of weight homeostasis is quite strong, there is growing evidence that the melanocortins also play a similar role in human obesity. A quantitative trait locus (QTL) associated with obesity in a human population was recently identi®ed near the POMC gene locus, 34 suggesting that mutations in POMC productionaprocessing may play a role in human obesity. Furthermore, a novel agouti-related transcript (ART, also known as agoutirelated protein or AGRP) has been identi®ed in both rodents and man. This protein is produced in the hypothalamus and has potent antagonist activity for both MC3-R and MC4-R, despite sharing considerable sequence homology to agouti protein. 35, 36 This homology, along with the expression pattern and pharmacological pro®le, suggests that AGRP plays a role in allowing speci®c melanocortin subtype (MC3-R and MC4-R) regulation similar to that observed with the agouti protein and MC1-R in pigmentaion control. Consistent with this hypothesis, expression levels of ART have recently been shown to be modulated by leptin in an inverse relationship to POMC. 37 The current model therefore suggests that the MC4-R is speci®cally switched between activation and inactivation by the action of two secreted hormones, MSH and AGRP.
Conclusion
The rodent data supporting the role of MC4-R regulation in weight homeostasis is compelling and the recent data supporting a similar function in humans will no doubt be expanded in the near future. This strong proof-of-concept, along with the rich history of therapeutic agents derived from G-protein coupled receptors, augurs well for the development of novel therapeutic anti-obesity agents targeted to the MC4-R.
